DK0862454T3 - CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner - Google Patents

CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner

Info

Publication number
DK0862454T3
DK0862454T3 DK96936385T DK96936385T DK0862454T3 DK 0862454 T3 DK0862454 T3 DK 0862454T3 DK 96936385 T DK96936385 T DK 96936385T DK 96936385 T DK96936385 T DK 96936385T DK 0862454 T3 DK0862454 T3 DK 0862454T3
Authority
DK
Denmark
Prior art keywords
ctla
csf
combination
treat infections
treat
Prior art date
Application number
DK96936385T
Other languages
English (en)
Inventor
Jacques Banchereau
Odille Djossou
Leopoldo Flores-Romo
Francois Fossiez
Pierre Golstein
Mala Krishna
J E Lebecque Serge
Richard Murray
Original Assignee
Schering Corp
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Inst Nat Sante Rech Med filed Critical Schering Corp
Application granted granted Critical
Publication of DK0862454T3 publication Critical patent/DK0862454T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK96936385T 1995-10-27 1996-10-23 CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner DK0862454T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US590995P 1995-10-27 1995-10-27
US56974295A 1995-12-08 1995-12-08
PCT/US1996/016315 WO1997015320A1 (en) 1995-10-27 1996-10-23 Novel uses of mammalian ctla-8 and related reagents

Publications (1)

Publication Number Publication Date
DK0862454T3 true DK0862454T3 (da) 2002-12-30

Family

ID=26674918

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96936385T DK0862454T3 (da) 1995-10-27 1996-10-23 CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner

Country Status (10)

Country Link
EP (1) EP0862454B1 (da)
JP (2) JP3253633B2 (da)
AT (1) ATE222768T1 (da)
AU (1) AU7439996A (da)
CA (1) CA2235951C (da)
DE (1) DE69623316T2 (da)
DK (1) DK0862454T3 (da)
ES (1) ES2181915T3 (da)
PT (1) PT862454E (da)
WO (1) WO1997015320A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2007106769A2 (en) 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
ES2465223T3 (es) 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
US20100310502A1 (en) * 2009-06-09 2010-12-09 Anders Linden Method of treating local infections in mammals
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
JP3501801B2 (ja) * 1990-08-23 2004-03-02 カイロン コーポレイション 組み換えコロニー刺激因子―１の使用
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
WO1995016458A1 (en) * 1993-12-13 1995-06-22 Sandoz Ltd. Il-6 therapy

Also Published As

Publication number Publication date
AU7439996A (en) 1997-05-15
EP0862454B1 (en) 2002-08-28
JPH10512293A (ja) 1998-11-24
DE69623316D1 (de) 2002-10-02
JP2002145799A (ja) 2002-05-22
ATE222768T1 (de) 2002-09-15
DE69623316T2 (de) 2003-04-17
CA2235951C (en) 2003-04-01
WO1997015320A1 (en) 1997-05-01
EP0862454A1 (en) 1998-09-09
CA2235951A1 (en) 1997-05-01
JP3253633B2 (ja) 2002-02-04
HK1015692A1 (en) 1999-10-22
ES2181915T3 (es) 2003-03-01
PT862454E (pt) 2002-11-29

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
DK0911033T3 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
DE3587434D1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
ITRM910922A1 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
DK1003546T3 (da) Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
ATE76579T1 (de) Interferon-zusammensetzungen.
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
NO982863L (no) Nye forbindelser med analgetisk effekt
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
DK139685A (da) Liposomer med inhalative allergener til behandling af allergier, fremgangsmaade til deres fremstilling og laegemidler indeholdende disseliposomer
ATE233570T1 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
NO962503L (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
FI952018A0 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskriptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon